Compare TOMZ & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TOMZ | IMNN |
|---|---|---|
| Founded | 1979 | 1982 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2M | 12.5M |
| IPO Year | N/A | 1985 |
| Metric | TOMZ | IMNN |
|---|---|---|
| Price | $0.70 | $3.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $3.50 | ★ $182.61 |
| AVG Volume (30 Days) | 16.0K | ★ 48.8K |
| Earning Date | 11-14-2025 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,688,341.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $68.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $2.99 |
| 52 Week High | $1.20 | $41.22 |
| Indicator | TOMZ | IMNN |
|---|---|---|
| Relative Strength Index (RSI) | 48.53 | 38.67 |
| Support Level | $0.70 | $3.39 |
| Resistance Level | $0.79 | $3.89 |
| Average True Range (ATR) | 0.03 | 0.24 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 54.04 | 2.82 |
TOMI Environmental Solutions Inc is a leader in bacteria decontamination and infectious disease control, offering environmentally friendly solutions for indoor air and surface disinfection and decontamination. Its flagship product, SteraMist, uses patented and registered Binary Ionization Technology (BIT) to deliver a low-percentage (7.8%) hydrogen peroxide-based fog or mist to affect all indoor environments and surface areas. Its product portfolio includes The SteraPak, The Surface Unit, The Transport, The NV+, The Environment System, SteraMist Integrated System, BIT Solution, and Custom Engineered System.
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).